Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
作者
Sundar Jagannath,Jesús G. Berdeja,Robert M. Rifkin,Craig E. Cole,Michael A. Thompson,Rosanna Ricafort,Amanda Scofield,Hesham Mohamed,Oumar Sy,Ravi Vij,William Bensinger